# EDGAR Filing Document

**Accession Number:** 0001849380
**File Stem:** 0001493152-25-025269
**Filing Date:** 2025-11
**Character Count:** 10948
**Document Hash:** 63049d9bf441e94fc7a84fd6babd7fb5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-025269.hdr.sgml**: 20251126

**ACCESSION NUMBER**: 0001493152-25-025269

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20231208

**FILED AS OF DATE**: 20251126

**DATE AS OF CHANGE**: 20251126

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Yu Jeffrey
- **CENTRAL INDEX KEY:** 0001991132

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40386
- **FILM NUMBER:** 251532202

**MAIL ADDRESS:**
- **STREET 1:** 10212 SUMMER MEADOW WAY
- **CITY:** GOLDEN OAK
- **STATE:** FL
- **ZIP:** 32836
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OneMedNet Corp
- **CENTRAL INDEX KEY:** 0001849380
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 862076743
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** TRIDENT COURT, 1 OAKCROFT ROAD
- **STREET 2:** CHESSINGTON
- **CITY:** SURREY
- **STATE:** X0
- **ZIP:** KT9 1BD
- **BUSINESS PHONE:** 011-44-208-090-2009

**MAIL ADDRESS:**
- **STREET 1:** TRIDENT COURT, 1 OAKCROFT ROAD
- **STREET 2:** CHESSINGTON
- **CITY:** SURREY
- **STATE:** X0
- **ZIP:** KT9 1BD

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Data Knights Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210304

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Yu Jeffrey<br><sub>(Last) (First) (Middle)</sub><br>6385 OLD SHADY OAK ROAD, SUITE 250<br><sub>(Street)</sub><br>EDEN PRAIRIE, MN 55344<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-12-08 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Medical Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>OneMedNet Corp [ ONMD ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-12-08 |  | P |  | 3300 | A | 1.31<sup>(1)</sup> | 2458424 | D |  |
| Common Stock | 2023-12-11 |  | P |  | 30 | A | 1.36<sup>(2)</sup> | 2458454 | D |  |
| Common Stock | 2023-12-12 |  | P |  | 3040 | A | 1.06<sup>(3)</sup> | 2461494 | D |  |
| Common Stock | 2023-12-13 |  | P |  | 50 | A | $1.09 | 2461544 | D |  |
| Common Stock | 2023-12-15 |  | P |  | 10 | A | $0.92 | 2461554 | D |  |
| Common Stock | 2023-12-27 |  | P |  | 10 | A | $1.03 | 2461564 | D |  |
| Common Stock | 2024-01-02 |  | P |  | 20 | A | $0.82 | 2461584 | D |  |
| Common Stock | 2024-01-04 |  | P |  | 180 | A | 0.84<sup>(4)</sup> | 2461764 | D |  |
| Common Stock | 2024-01-08 |  | P |  | 10 | A | $0.83 | 2461774 | D |  |
| Common Stock | 2024-01-09 |  | P |  | 100 | A | $0.86 | 2461874 | D |  |
| Common Stock | 2024-01-10 |  | P |  | 20 | A | $0.85 | 2461894 | D |  |
| Common Stock | 2024-01-12 |  | P |  | 20 | A | $0.81 | 2461914 | D |  |
| Common Stock | 2024-01-16 |  | P |  | 15 | A | 0.75<sup>(5)</sup> | 2461929 | D |  |
| Common Stock | 2024-01-17 |  | P |  | 362 | A | 0.61<sup>(6)</sup> | 2462291 | D |  |
| Common Stock | 2024-01-19 |  | P |  | 60 | A | 0.48<sup>(7)</sup> | 2462351 | D |  |
| Common Stock | 2024-01-19 |  | A |  | 45000<sup>(15)</sup> | A | $0.00 | 2507351 | D |  |
| Common Stock | 2024-01-22 |  | P |  | 5035 | A | 0.49<sup>(8)</sup> | 2512386 | D |  |
| Common Stock | 2024-01-23 |  | P |  | 720 | A | 0.52<sup>(9)</sup> | 2513106 | D |  |
| Common Stock | 2024-01-24 |  | P |  | 740 | A | 0.55<sup>(10)</sup> | 2513846 | D |  |
| Common Stock | 2024-01-25 |  | P |  | 2304 | A | 0.55<sup>(11)</sup> | 2516150 | D |  |
| Common Stock | 2024-01-26 |  | P |  | 5386 | A | 0.56<sup>(12)</sup> | 2521536 | D |  |
| Common Stock | 2024-01-29 |  | P |  | 950 | A | 1.04<sup>(13)</sup> | 2522486 | D |  |
| Common Stock | 2024-01-30 |  | P |  | 400 | A | 1.14<sup>(14)</sup> | 2522886 | D |  |
| Common Stock |  |  |  |  |  |  |  | 1311970 | I | By trust for children<sup>(16)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.28 to $1.31, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in the footnotes of this report.

(2) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.35 to $1.37, inclusive.

(3) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.09, inclusive.

(4) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.82 to $0.85, inclusive.

(5) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.71 to $0.78, inclusive.

(6) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.56 to $0.73, inclusive.

(7) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.44 to $0.62, inclusive.

(8) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.44 to $0.62, inclusive.

(9) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.48 to $0.54, inclusive.

(10) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.52 to $0.60, inclusive.

(11) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.50 to $0.60, inclusive.

(12) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.51 to $0.60, inclusive.

(13) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.07, inclusive.

(14) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.48, inclusive.

(15) Represents restricted stock units ("RSUs") granted as director compensation under the OneMedNet Corporation 2022 Equity Incentive Plan for board service in fiscal year 2024. Each RSU represents the contingent right to receive one share of the issuer's common stock. The RSUs vested on December 31, 2024.

(16) The shares are held by trust with an independent trustee, in which the reporting person has no investment control. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the shares for purposes of Section 16 or for any other purpose.

**Signature:** /s/ Robert Golden, Attorney-in-Fact  
**Date:** 2025-11-26

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**